Belarte-Tornero Laia C, Valdivielso-Moré Sandra, Vicente Elcano Miren, Solé-González Eduard, Ruíz-Bustillo Sonia, Calvo-Fernández Alicia, Subinara Isaac, Cabero Paula, Soler Cristina, Cubero-Gallego Héctor, Vaquerizo Beatriz, Farré Núria
Heart Failure Unit, Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain.
Heart Diseases Biomedical Research Group (GREC), IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
J Clin Med. 2021 Jan 17;10(2):323. doi: 10.3390/jcm10020323.
The prevalence and prognostic value of chronic heart failure (CHF) in the setting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has seldom been studied. The aim of this study was to analyze the prevalence and prognosis of CHF in this setting.
This single-center study included 829 consecutive patients with SARS-CoV-2 infection from February to April 2020. Patients with a previous history of CHF were matched 1:2 for age and sex. We analyze the prognostic value of pre-existing CHF. Prognostic implications of N terminal pro brain natriuretic peptide (NT-proBNP) levels on admission in the CHF cohort were explored.
A total of 129 patients (43 CHF and 86 non-CHF) where finally included. All-cause mortality was higher in CHF patients compared to non-CHF patients (51.2% vs. 29.1%, = 0.014). CHF was independently associated with 30-day mortality (hazard ratio (HR) 2.3, confidence interval (CI) 95%: 1.26-2.4). Patients with CHF and high-sensitivity troponin T < 14 ng/L showed excellent prognosis. An NT-proBNP level > 2598 pg/mL on admission was associated with higher 30-day mortality in patients with CHF.
All-cause mortality in CHF patients hospitalized due to SARS-CoV-2 infection was 51.2%. CHF was independently associated with all-cause mortality (HR 2.3, CI 95% 1.26-4.2). NT-proBNP levels could be used for stratification risk purposes to guide medical decisions if larger studies confirm this finding.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染背景下慢性心力衰竭（CHF）的患病率及预后价值鲜有研究。本研究旨在分析此背景下CHF的患病率及预后情况。
这项单中心研究纳入了2020年2月至4月连续收治的829例SARS-CoV-2感染患者。有CHF既往史的患者按年龄和性别以1:2进行匹配。我们分析了既往存在的CHF的预后价值。探讨了CHF队列中入院时N末端脑钠肽前体（NT-proBNP）水平的预后意义。
最终共纳入129例患者（43例CHF患者和86例非CHF患者）。CHF患者的全因死亡率高于非CHF患者（51.2%对29.1%，P = 0.014）。CHF与30天死亡率独立相关（风险比（HR）2.3，95%置信区间（CI）：1.26 - 2.4）。CHF且高敏肌钙蛋白T < 14 ng/L的患者预后良好。入院时NT-proBNP水平> 2598 pg/mL与CHF患者较高的30天死亡率相关。
因SARS-CoV-2感染住院的CHF患者的全因死亡率为51.2%。CHF与全因死亡率独立相关（HR 2.3，95% CI 1.26 - 4.2）。如果更大规模研究证实这一发现，NT-proBNP水平可用于分层风险以指导医疗决策。
